Update on treatment of cytomegalovirus infection in pregnancy and of the newborn with congenital cytomegalovirus

Current Opinion in Infectious Diseases

Volumn 29, Issue 6, 2016, Pages 615-624

  Rawlinson, William D ^a,b   Hamilton, Stuart T ^a   Van Zuylen, Wendy J ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antivirals; Congenital cytomegalovirus; Ganciclovir; Hyperimmune globulin; Therapy

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; HYPERIMMUNE GLOBULIN; VALGANCICLOVIR; IMMUNOGLOBULIN;

ANTIVIRAL THERAPY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FETUS DEATH; HUMAN; INFECTION PREVENTION; MATERNAL TREATMENT; NEWBORN; NEWBORN DEATH; NEWBORN INFECTION; NONHUMAN; PERCEPTION DEAFNESS; PREGNANCY; PREGNANT WOMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; VIRUS TRANSMISSION; CYTOMEGALOVIRUS; FEMALE; FETUS DISEASE; PREGNANCY COMPLICATION; PREVENTION AND CONTROL; TRANSMISSION; VERTICAL TRANSMISSION;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FETAL DISEASES; HUMANS; IMMUNOGLOBULINS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84986204832     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000317     Document Type: Review

References (65)

1. McMullan BJ, Palasanthiran P, Jones CA, et al. Congenital cytomegalovirus: Time to diagnosis, management and clinical sequelae in Australia: Opportunities for earlier identification. Med J Aust 2011; 194: 625-629.
2. Cannon MJ, Griffiths PD, Aston V, Rawlinson WD. Universal newborn screening for congenital CMV infection: What is the evidence of potential benefit? Rev Med Virol 2014; 24: 291-307.
3. Cannon MJ, Westbrook K, Levis D, et al. Awareness of and behaviors related to child-to-mother transmission of cytomegalovirus. Prev Med 2012; 54: 351-357.
4. Ville Y, Leruez-Ville M. Managing infections in pregnancy. Curr Opin Infect Dis 2014; 27: 251-257.
5. Nigro G, Adler SP, La Torre R, Best AM. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005; 353: 1350-1362.
6. Revello MG, Lazzarotto T, Guerra B, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 2014; 370: 1316-1326.
7. Neirukh T, Qaisi A, Saleh N, et al. Seroprevalence of cytomegalovirus among pregnant women and hospitalized children in Palestine. BMC Infect Dis 2013; 13: 528.
8. Willame A, Blanchard-Rohner G, Combescure C, et al. Awareness of cytomegalovirus infection among pregnant women in Geneva, Switzerland: A cross-sectional study. Int J Environ Res Public Health 2015; 12: 15285-15297.
9. Cordier A, Guitton S, Vauloup-Fellous C, et al. Awareness of cytomegalovirus infection among pregnantwomen in France. JClin Virol 2012; 53: 332-337.
10. Cordier AG, Guitton S, Vauloup-Fellous C, et al. Awareness and knowledge of congenital cytomegalovirus infection among healthcare providers in France. J Clin Virol 2012; 55: 158-163.
11. Jeon J, Victor M, Adler SP, et al. Knowledge and awareness of congenital cytomegalovirus among women. Infect Dis Obstet Gynecol 2006; 2006: 80383.
12. Johnson JM, Anderson BL. Cytomegalovirus: Should we screen pregnant women for primary infection? Am J Perinatol 2013; 30: 121-124.
13. Kling C, Kabelitz D. Congenital HCMV and assisted reproduction: Why not use the chance for primary screening? Arch Gynecol Obstet 2015; 291: 1205-1211.
14. Demmler-Harrison GJ. Congenital cytomegalovirus: Public health action towards awareness, prevention, and treatment. J Clin Virol 2009; 46 (Suppl 4): S1-S5.
15. Manicklal S, Emery VC, Lazzarotto T, et al. The 'silent' global burden of congenital cytomegalovirus. Clin Microbiol Rev 2013; 26: 86-102.
16. Griffiths P, Lumley S. Cytomegalovirus. Curr Opin Infect Dis 2014; 27: 554-559.
17. Kirby T. Congenital cytomegalovirus: A neglected health problem. Lancet Infect Dis 2016; 16: 900-901.
18. Scott GM, Chow SS, Craig ME, et al. Cytomegalovirus infection during pregnancy with maternofetal transmission induces a proinflammatory cytokine bias in placenta and amniotic fluid. J Infect Dis 2012; 205: 1305-1310.
19. Hamilton ST, Scott G, Naing Z, et al. Human cytomegalovirus-induces cytokine changes in the placenta with implications for adverse pregnancy outcomes. PLoS One 2012; 7: E52899.
20. Maidji E, Nigro G, Tabata T, et al. Antibody treatment promotes compensation for human cytomegalovirus-induced pathogenesis and a hypoxia-like condition in placentas with congenital infection. Am J Pathol 2010; 177: 1298-1310.
21. Iwasenko JM, Howard J, Arbuckle S, et al. Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy. J Infect Dis 2011; 203: 1526-1533.
22. van Zuylen WJ, Ford CE, Wong DD, Rawlinson WD. Human cytomegalovirus modulates expression of noncanonical Wnt receptor ROR2 to alter trophoblast migration. J Virol 2015; 90: 1108-1115.
23. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003; 289: 1008-1011.
24. Jü ckstock J, Rothenburger M, Friese K, Traunmü ller F. Passive immunization against congenital cytomegalovirus infection: Current state of knowledge. Pharmacology 2015; 95: 209-217.
25. Morioka I, Sonoyama A, Tairaku S, et al. Awareness of and knowledge about mother-to-child infections in Japanese pregnant women. Congenit Anom (Kyoto) 2014; 54: 35-40.
26. Jacob CL, Lamorte L, Sepulveda E, et al. Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus. Virology 2013; 444: 140-147.
27. Wang C, Zhang X, Bialek S, Cannon MJ. Attribution of congenital cytomegalovirus infection to primary versus nonprimary maternal infection. Clin Infect Dis 2011; 52: E11-e13.
28. Buxmann H, Stackelberg OM, Schlosser RL, et al. Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: A retrospective analysis. J Perinat Med 2012; 40: 439-446.
29. Nigro G, Capretti I, Manganello AM, et al. Primary maternal cytomegalovirus infections during pregnancy: Association of CMV hyperimmune globulin with gestational age at birth and birth weight. J Matern Fetal Neonatal Med 2014; 28: 168-171.
30. Japanese Congenital Cytomegalovirus Infection Immunoglobulin Fetal Therapy Study Group. A trial of immunoglobulin fetal therapy for symptomatic congenital cytomegalovirus infection. J Reprod Immunol 2012; 95: 73-79.
31. Visentin S, Manara R, Milanese L, et al. Early primary cytomegalovirus infection in pregnancy: Maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis 2012; 55: 497-503.
32. Nigro G, Adler SP, Gatta E, et al. Fetal hyperechogenic bowel may indicate congenital cytomegalovirus disease responsive to immunoglobulin therapy. J Matern Fetal Neonatal Med 2012; 25: 2202-2205.
33. Nigro G, Adler SP, Parruti G, et al. Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy: A case-control study of the outcome in children. J Infect Dis 2012; 205: 215-227.
34. Pescovitz MD. Absence of teratogenicity of oral ganciclovir used during early pregnancy in a liver transplant recipient. Transplantation 1999; 67: 758-759.
35. Ratanajamit C, Vinther Skriver M, Jepsen P, et al. Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: A population-based observational study. Scand J Infect Dis 2003; 35: 255-259.
36. Brandy RC, Schleiss MR, Witte DP, et al. Placental transfer of ganciclovir in a woman with acquired immunodeficiency syndrome and cytomegalovirus disease. Pediatr Infect Dis J 2002; 21: 796-797.
37. Alvarez-McLeod A, Havlik J, Drew KE. Foscarnet treatment of genital infection due to acyclovir-resistant herpes simplex virus type 2 in a pregnant patient with AIDS: Case report. Clin Infect Dis 1999; 29: 937-938.
38. Leruez-Ville M, Ghout I, Bussieres L, et al. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. Am J Obstet Gynecol 2016. [Epub ahead of print]
39. Miller BW, Howard TK, Goss JA, et al. Renal transplantation one week after conception. Transplantation 1995; 60: 1353-1354.
40. Honein MA, Paulozzi LJ, Cragan JD, Correa A. Evaluation of selected characteristics of pregnancy drug registries. Teratology 1999; 60: 356-364.
41. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462-1470.
42. Griffiths PD, Feinberg JE, Fry J, et al. The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1998; 177: 57-64.
43. Emery VC, Sabin C, Feinberg JE, et al. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: Baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1999; 180: 695-701.
44. Puliyanda DP, Silverman NS, Lehman D, et al. Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient. Transpl Infect Dis 2005; 7: 71-74.
45. Wilton LV, Pearce GL, Martin RM, et al. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998; 105: 882-889.
46. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol 2004; 70: 201-207.
47. Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010; 304: 859-866.
48. Jacquemard F, Yamamoto M, Costa JM, et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. Br J Obstet Gynaecol 2007; 114: 1113-1121.
49. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
50. Nigro G, Scholz H, Bartmann U. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: A two-regimen experience. J Pediatr 1994; 124: 318-322.
51. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: A randomized, controlled trial. J Pediatr 2003; 143: 16-25.
52. Kimberlin DW, Jester PM, Sanchez PJ, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 2015; 372: 933-943.
53. Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: Results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1997; 175: 1080-1086.
54. Michaels MG, Greenberg DP, Sabo DL, Wald ER. Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr Infect Dis J 2003; 22: 504-509.
55. El-Sayed MF, Goldfarb DM, Fulford M, Pernica JM. Severe late-onset multisystem cytomegalovirus infection in a premature neonate previously treated for congenital infection. BMC Pediatr 2013; 13: 142.
56. Lombardi G, Garofoli F, Villani P, et al. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. Eur J Clin Microbiol Infect Dis 2009; 28: 1465-1470.
57. del Rosal T, Baquero-Artigao F, Blazquez D, et al. Treatment of symptomatic congenital cytomegalovirus infection beyond the neonatal period. J Clin Virol 2012; 55: 72-74.
58. Hamilton ST, van Zuylen W, Shand A, et al. Prevention of congenital cytomegalovirus complications by maternal and neonatal treatments: A systematic review. Rev Med Virol 2014; 24: 420-433.
59. Hamilton ST, Milbradt J, Marschall M, Rawlinson WD. Human cytomegalovirus replication is strictly inhibited by siRNAs targeting UL54, UL97 or UL122/123 gene transcripts. PLoS One 2014; 9: E97231.
60. Reichman O, Miskin I. Preconception screening for cytomegalovirus: An effective preventive approach. Biomed Res Int 2014; 2014: 135416.
61. Adler SP, Finney JW, Manganello AM, Best AM. Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. J Pediatr 2004; 145: 485-491.
62. Dasari V, Smith C, Zhong J, et al. Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus. J Gen Virol 2011; 92: 1021-1031.
63. Bialas KM, Permar SR. The March towards a vaccine for congenital CMV: Rationale and models. PLoS Pathog 2016; 12: E1005355.
64. Schleiss MR. Current status of cytomegalovirus vaccines: 2016. In: ELS. Chichester: John Wiley & Sons; http://www.els.net/WileyCDA/ElsArticle/refId-a0024788.html.
65. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009; 360: 1191-1199.